Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

6.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.6K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

120
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
120
Statistical Software for Data Analysis and Clinical Trials01:12

Statistical Software for Data Analysis and Clinical Trials

492
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
492
Study Design in Statistics01:15

Study Design in Statistics

7.8K
A study design is a set of techniques that allow a researcher to collect and analyze data from different variables defined for a specific research problem. Statistics is commonly for effective study design and more robust experiments,
Does aspirin reduce the risk of heart attacks? Is one brand of fertilizer more effective at growing roses than another? Is fatigue as dangerous to a driver as the influence of alcohol? Questions like these are answered using randomized experiments with proper...
7.8K
Study Designs in Epidemiology01:20

Study Designs in Epidemiology

180
Epidemiological study designs are fundamental tools for investigating the distribution, determinants, and control of health conditions in populations. They help researchers understand the relationships between exposures and outcomes, and they broadly fall into two categories: "observational" and "experimental" studies.
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
180
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

38
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
38

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extracting patient reported cannabis use and reasons for use from electronic health records: a benchmarking study of large language models.

medRxiv : the preprint server for health sciences·2026
Same author

Five Data-Informed Principles for Advancing Inclusive Research in Clinical Trials: A Pharma Perspective.

Advances in therapy·2025
Same author

R-index: a standardized representativeness metric for benchmarking diversity, equity, and inclusion in biopharmaceutical clinical trial development.

EClinicalMedicine·2025
Same author

Two-Layer Retrieval-Augmented Generation Framework for Low-Resource Medical Question Answering Using Reddit Data: Proof-of-Concept Study.

Journal of medical Internet research·2025
Same author

Investigating Data Diversity and Model Robustness of AI Applications in Palliative Care and Hospice: Protocol for Scoping Review.

JMIR research protocols·2024
Same author

Barriers to Clinical Trial Implementation Among Community Care Centers.

JAMA network open·2024

Related Experiment Video

Updated: Jun 4, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K

POP-REFINE: A Comprehensive Framework for Evaluating and Optimizing Representativeness in Clinical Trials.

Corey M Benedum1, Somnath Sarkar2,3, Selen Bozkurt4

  • 1Genentech, Inc., South San Francisco, CA, USA.

Clinical Pharmacology and Therapeutics
|December 28, 2024
PubMed
Summary
This summary is machine-generated.

Clinical trials often lack diverse populations, leading to health inequities. A new framework, Population Optimization, Representativeness Evaluation, and Fine-tuning (POREF), quantifies and improves trial representativeness for equitable treatment access.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.4K
The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time
06:05

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time

Published on: February 19, 2021

1.2K

Related Experiment Videos

Last Updated: Jun 4, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.4K
The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time
06:05

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time

Published on: February 19, 2021

1.2K

Area of Science:

  • Clinical trial methodology
  • Health equity research
  • Biostatistics

Background:

  • Historically, clinical trials have underrepresented diverse populations, perpetuating health inequities.
  • Ensuring representativeness is vital for treatment appropriateness, equitable access to novel therapies, and generalizability of study findings.
  • Regulatory agencies increasingly focus on the impact of novel therapies across all patient populations.

Purpose of the Study:

  • To introduce a novel framework for quantifying and enhancing the representativeness of clinical trial populations.
  • To address the underdeveloped systematic approaches for measuring and optimizing clinical trial diversity.
  • To support regulatory and internal decision-making processes for more inclusive clinical research.

Main Methods:

  • Developed the Population Optimization, Representativeness Evaluation, and Fine-tuning (POREF) framework.
  • Included methods for evaluating overall and subgroup representativeness.
  • Applied the framework to nine oncology trials using a de-identified electronic health record database to quantify eligible population representativeness.

Main Results:

  • Quantified the representativeness of eligible populations for nine oncology clinical trials.
  • Demonstrated the framework's ability to identify drivers of non-representativeness.
  • Showcased the optimization of eligibility criteria to achieve more representative patient populations.

Conclusions:

  • The POREF framework offers a comprehensive, data-driven approach to enhance clinical trial representativeness.
  • This systematic method can improve the generalizability of study results and reduce post-marketing disparities.
  • The framework is adaptable across various disease indications and can be extended to evaluate enrolled samples.